Novel approaches to pediatric leukemia treatment

References

• National Cancer Institute. SEER (Surveillance, Epidemiology, and End Results) Statistics Review, 1975-2007. 2010
   Google Scholar
• Pui CH, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol 2011;29:551-65
   PubMed Web of Science ®Google Scholar
• Moricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 2008;111:4477-89
   PubMed Web of Science ®Google Scholar
• Bhojvani D, Pui CH. Relapsed childhood acute lymphoblastic leukaemia. Lancet Oncol 2013;14:e205-17
   Google Scholar
• Kaspers GJ. Pediatric acute myeloid leukemia. Expert Rev Anticancer Ther 2012;12:405-13
   PubMed Web of Science ®Google Scholar
• Kaspers GJ, Zimmermann M, Reinhardt D, et al. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. J Clin Oncol 2013;31:599-607
   PubMed Web of Science ®Google Scholar
• Kurmasheva RT, Houghton PJ. Pediatric oncology. Curr Opin Chem Biol 2007;11:424-32
   Google Scholar
• Hasle H. A critical review of which children with acute myeloid leukaemia need stem cell procedures. Br J Haematol 2014;166:23-33
   Google Scholar
• Meadows AT, Friedman DL, Neglia JP, et al. Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort. J Clin Oncol 2009;27:2356-62
   PubMed Web of Science ®Google Scholar
• Mulrooney DA, Yeazel MW, Kawashima T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 2009;339:b4606
   PubMed Web of Science ®Google Scholar
• Mackall CL. In search of targeted therapies for childhood cancer. Front Oncol 2011;1:18
   PubMedGoogle Scholar
• Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730-7
   PubMed Web of Science ®Google Scholar
• Schlieben S, Borkhardt A, Reinisch I, et al. Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL): a prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM 90 and CoALL-05-92. Leukemia 1996;10:957-63
   PubMed Web of Science ®Google Scholar
• Arico M, Valsecchi MG, Camitta B, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 2000;342:998-1006
   PubMed Web of Science ®Google Scholar
• Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7
   PubMed Web of Science ®Google Scholar
• Barr RD. Imatinib mesylate in children and adolescents with cancer. Pediatr Blood Cancer 2010;55:18-25
   PubMed Web of Science ®Google Scholar
• Schultz KR, Carroll A, Heerema NA, et al. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children’s Oncology Group Study AALL0031. Leukemia 2014;28:1467-71
   PubMed Web of Science ®Google Scholar
• Hunger SP. Tyrosine kinase inhibitor use in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematology 2011;361-5
   Google Scholar
• Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251-9
   PubMed Web of Science ®Google Scholar
• La Rosee P, Holm-Eriksen S, Konig H, et al. Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients with nilotinib. Haematologica 2008;93:765-9
   PubMedGoogle Scholar
• O’Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005;65:4500-5
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 2012;367:2075-88
   PubMed Web of Science ®Google Scholar
• Iacobucci I, Lonetti A, Messa F, et al. Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance. Blood 2008;112:3847-55
   PubMed Web of Science ®Google Scholar
• Den Boer ML, van Slegtenhorst M, De Menezes RX, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol 2009;10:125-34
   PubMed Web of Science ®Google Scholar
• Harvey RC, Kang H, Roberts KG, et al. Development and validation of a highly sensitive and specific gene expression classifier to prospectively screen and identify B-precursor acute lymphoblastic leukemia (ALL) patients with a Philadelphia chromosome-like (“Ph-like” or “BCR-ABL1-like”) signature for therapeutic targeting and clinical intervention. Blood 2013;122:826; abstract
   Web of Science ®Google Scholar
• Masuzawa A, Kiyotani C, Osumi T, et al. Poor responses to tyrosine kinase inhibitors in a child with precursor B-cell acute lymphoblastic leukemia with SNX2-ABL1 chimeric transcript. Eur J Haematol 2014;92:263-7
   PubMed Web of Science ®Google Scholar
• Roberts KG, Morin RD, Zhang J, et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell 2012;22:153-66
   PubMed Web of Science ®Google Scholar
• Clarke S, O’Reilly J, Romeo G, Cooney J. NUP214-ABL1 positive T-cell acute lymphoblastic leukemia patient shows an initial favorable response to imatinib therapy post relapse. Leuk Res 2011;35:e131-3
   Google Scholar
• Beghini A, Ripamonti CB, Cairoli R, et al. KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of a internal tandem duplication. Haematologica 2004;89:920-5
   PubMed Web of Science ®Google Scholar
• Pollard JA, Alonzo TA, Gerbing RB, et al. Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Blood 2010;115:2372-9
   PubMed Web of Science ®Google Scholar
• Wang YY, Zhao LJ, Wu CF, et al. C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice. Proc Natl Acad Sci USA 2011;108:2450-5
   PubMed Web of Science ®Google Scholar
• Meshinchi S, Appelbaum FR. Structural and functional alterations of FLT3 in acute myeloid leukemia. Clin Cancer Res 2009;15:4263-9
   PubMed Web of Science ®Google Scholar
• Knapper S. The clinical development of FLT3 inhibitors in acute myeloid leukemia. Expert Opin Investig Drugs 2011;20:1377-95
   PubMed Web of Science ®Google Scholar
• Swords R, Freeman C, Giles F. Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia. Leukemia 2012;26:2176-85
   PubMed Web of Science ®Google Scholar
• Smith BD, Levis M, Beran M, et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 2004;103:3669-76
   PubMed Web of Science ®Google Scholar
• Zhang W, Konopleva M, Shi YX, et al. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst 2008;100:184-98
   PubMed Web of Science ®Google Scholar
• Goemans BF, Zwaan CM, Cloos J, et al. FLT3 and KIT mutated pediatric acute myeloid leukemia (AML) samples are sensitive in vitro to the tyrosine kinase inhibitor SU11657. Leuk Res 2010;34:1302-7
   Google Scholar
• Ravandi F, Cortes JE, Jones D, et al. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol 2010;28:1856-62
   PubMed Web of Science ®Google Scholar
• Inaba H, Rubnitz JE, Coustan-Smith E, et al. Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. J Clin Oncol 2011;29:3293-300
   PubMed Web of Science ®Google Scholar
• Williams AB, Nguyen B, Li L, et al. Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors. Leukemia 2012;27:48-55
   Google Scholar
• Carmena M, Earnshaw WC. The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 2003;4:842-54
   PubMed Web of Science ®Google Scholar
• Moore AS, Blagg J, Linardopoulos S, Pearson AD. Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias. Leukemia 2010;24:671-8
   PubMed Web of Science ®Google Scholar
• Hartsink-Segers SA, Zwaan CM, Exalto C, et al. Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target. Leukemia 2013;27:560-8
   PubMed Web of Science ®Google Scholar
• Löwenberg B, Muus P, Ossenkoppele G, et al. Phase I/II study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. Blood 2011;118:6030-6
   PubMed Web of Science ®Google Scholar
• Goldberg SL, Fenaux P, Craig MD, et al. Phase 2 study of MLN8237, an investigational aurora A kinase (AAK) inhibitor in patients with acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS). Blood 2010;116:3273; abstract
   Google Scholar
• Maris JM, Morton CL, Gorlick R, et al. Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer 2010;55:26-34
   PubMed Web of Science ®Google Scholar
• Martelli AM, Chiarini F, Evangelisti C, et al. Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. Oncotarget 2012;3:371-94
   Google Scholar
• Maira SM, Stauffer F, Brueggen J, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008;7:1851-63
   PubMed Web of Science ®Google Scholar
• Schult C, Dahlaus M, Glass A, et al. The dual kinase inhibitor NVP-BEZ235 in combination with cytotoxic drugs exerts anti-proliferative activity towards acute lymphoblastic leukemia cells. Anticancer Res 2012;32:463-74
   PubMed Web of Science ®Google Scholar
• Park S, Chapuis N, Tamburini J, et al. Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica 2010;95:819-28
   PubMed Web of Science ®Google Scholar
• Weisberg E, Liu Q, Zhang X, et al. Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells. PLoS ONE 2013;8:e56473
   Google Scholar
• Maude SL, Tasian SK, Vincent T, et al. Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood 2012;120:3510-18
   PubMed Web of Science ®Google Scholar
• Daver N, Cortes J. Molecular targeted therapy in acute myeloid leukemia. Hematology (Am Soc Hematol Educ Program) 2012;17(Suppl1):S59-62
   Google Scholar
• Weisberg E, Liu Q, Nelson E, et al. Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors. Leukemia 2012;26:2233-44
   PubMed Web of Science ®Google Scholar
• Novotny-Diermayr V, Hart S, Goh KC, et al. The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML. Blood Cancer J 2012;2:e69
   PubMed Web of Science ®Google Scholar
• Wright JJ. Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy. Clin Cancer Res 2010;16:4094-104
   PubMed Web of Science ®Google Scholar
• Jagani Z, Song K, Kutok JL, et al. Proteasome inhibition causes regression of leukemia and abrogates BCR-ABL-induced evasion of apoptosis in part through regulation of forkhead tumor suppressors. Cancer Res 2009;69:6546-55
   PubMed Web of Science ®Google Scholar
• Hideshima T, Mitsiades C, Akiyama M, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 2003;101:1530-4
   PubMed Web of Science ®Google Scholar
• Horton TM, Pati D, Plon SE, et al. A phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children’s Oncology Group study. Clin Cancer Res 2007;13:1516-22
   PubMed Web of Science ®Google Scholar
• Houghton PJ, Morton CL, Kolb EA, et al. Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. Pediatr Blood Cancer 2008;50:37-45
   PubMed Web of Science ®Google Scholar
• Attar EC, De Angelo DJ, Supko JG, et al. Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. Clin Cancer Res 2008;14:1446-54
   PubMed Web of Science ®Google Scholar
• Bastian L, Hof J, Pfau M, et al. Synergistic activity of bortezomib and HDACi in preclinical models of B-cell precursor acute lymphoblastic leukemia via modulation of p53, PI3K/AKT, and NF-kappaB. Clin Cancer Res 2013;19:1445-57
   PubMed Web of Science ®Google Scholar
• Wang AH, Wei L, Chen L, et al. Synergistic effect of bortezomib and valproic acid treatment on the proliferation and apoptosis of acute myeloid leukaemia and myelodysplastic syndrome cells. Ann Hematol 2011;90:917-31
   Google Scholar
• Brown RE, Bostrom B, Zhang PL. Morpho-proteomics and bortezomib/dexamethasone-induced response in relapsed acute lymphoblastic leukemia. Ann Clin Lab Sci 2004;34:203-5
   PubMed Web of Science ®Google Scholar
• Messinger Y, Gaynon P, Raetz E, et al. Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the Therapeutic Advances in Childhood Leukemia (TACL) consortium. Pediatr Blood Cancer 2010;55:254-9
   PubMed Web of Science ®Google Scholar
• Messinger YH, Gaynon PS, Sposto R, et al. Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia lymphoma (TACL) study. Blood 2012;120:285-90
   PubMed Web of Science ®Google Scholar
• Lancet JE, Duong VH, Winton EF, et al. A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias. Clin Cancer Res 2011;17:1140-6
   Google Scholar
• McBride A, Klaus JO, Stockert-Goldstein K. Carfilzomib: a second-generation proteasome inhibitor for the treatment of multiple myeloma. Am J Health Syst Pharm 2015;72:353-60
   PubMed Web of Science ®Google Scholar
• Fulda S. Exploiting apoptosis pathways for the treatment of pediatric cancers. Pediatr Blood Cancer 2009;53:533-6
   Google Scholar
• Lock R, Carol H, Houghton PJ, et al. Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr Blood Cancer 2008;50:1181-9
   PubMed Web of Science ®Google Scholar
• Urtisha KA, Edwards AY, Wang LS, et al. Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemia (ALL). Blood 2013;121:2689-703
   Google Scholar
• Schnell S, Van Vlierberghe P, Ferrando A. The molecular basis of T-cell acute lymphoblastic leukemia. Hematol Educ 2011;1-8
   Google Scholar
• Real PJ, Tosello V, Palomero T, et al. Inhibition of NOTCH1 signaling and glucocorticoid therapy in T-ALL. Blood 2008;112(Suppl1):298; abstract
   Google Scholar
• Fandy TE. Development of DNA methyltransferase inhibitors for the treatment of neoplastic diseases. Curr Med Chem 2009;16:2075-85
   PubMed Web of Science ®Google Scholar
• Lucas DM, Alinari L, West DA, et al. The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo. PLoS One 2010;5:e10941
   PubMed Web of Science ®Google Scholar
• Gottlicher M, Minucci S, Zhu P, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001;20:6969-78
   PubMed Web of Science ®Google Scholar
• Xie C, Edwards H, Lograsso SB, et al. Valproic acid synergistically enhances the cytotoxicity of clofarabine in pediatric acute myeloid myeloid leukemia cells. Pediatr Blood Cancer 2012;59:1245-51
   Google Scholar
• Lane S, Gill D, McMillan NA, et al. Valproic acid combined with cytosine arabinoside in elderly patients with acute myeloid leukemia has in vitro but limited clinical activity. Leuk Lymphoma 2012;53:1077-83
   PubMed Web of Science ®Google Scholar
• Kuendgen A, Schmid M, Schlenk R, et al. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer 2006;106:112-19
   PubMed Web of Science ®Google Scholar
• Mummery A, Narendran A, Lee KY. Targeting epigenetics through histone deacetylase inhibitors in acute lymphoblastic leukemia. Curr Cancer Drug Targets 2011;11:882-93
   PubMed Web of Science ®Google Scholar
• Bernt KM, Armstrong SA. Targeting epigenetic programs in MLL-rearranged leukemias. Hematology (Am Soc Hematol Educ Program) 2011;354-60
   Google Scholar
• Daigle SR, Olhava EJ, Therkelsen CA, et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 2011;20:53-65
   PubMed Web of Science ®Google Scholar
• Chen L, Deshpande AJ, Banka D, et al.Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase DOT1L. Leukemia 2013;27:813-22
   Google Scholar
• Yu W, Chory EJ, Wernimont AK, et al. Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors. Nat Commun 2012;3:1288
   PubMed Web of Science ®Google Scholar
• Denis GV. Bromodomain coactivators in cancer, obesity, type 2 diabetes, and inflammation. Discov Med 2010;10:489-99
   PubMed Web of Science ®Google Scholar
• Filippakopoulos P, Qi J, Picaud S, et al. Selective inhibition of BET bromodomains. Nature 2010;468:1067-73
   PubMed Web of Science ®Google Scholar
• Zuber J, Shi J, Wang E, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011;478:524-8
   PubMed Web of Science ®Google Scholar
• Dawson MA, Prinjha RK, Dittmann A, et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 2011;478:529-33
   PubMed Web of Science ®Google Scholar
• Slany RK. The molecular biology of mixed lineage leukemia. Haematologica 2009;94:984-93
   PubMed Web of Science ®Google Scholar
• Thiel AT, Huang J, Lei M, Hua X. Menin as a hub controlling mixed lineage leukemia. Bioessays 2012;34:771-80
   PubMed Web of Science ®Google Scholar
• Grembecka J, He S, Shi A, et al. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nat Chem Biol 2012;8:277-84
   PubMed Web of Science ®Google Scholar
• Srinivasan RS, Nesbit JB, Marrero L, et al. The synthetic peptide PFWT disrupts AF4-AF9 protein complexes and induces apoptosis in t(4;11) leukemia cells. Leukemia 2004;18:1364-72
   Google Scholar
• Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-11
   PubMed Web of Science ®Google Scholar
• Löwenberg B, van Putten W, Theobald M, et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med 2003;349:743-52
   PubMed Web of Science ®Google Scholar
• Rombouts EJ, Pavic B, Löwenberg B, Ploemacher RE. Relation between CXCR-4 expression, Flt3 mutations and unfavorable prognosis of adult acute myeloid leukemia. Blood 2004;104:550-7
   PubMed Web of Science ®Google Scholar
• Konoplev S, Rassidakis GZ, Estey E, et al. Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype. Cancer 2007;109:1152-6
   PubMed Web of Science ®Google Scholar
• Carter BZ, Miella M, Altieri DC, Andreeff M. Cytokine-regulated expression of survivin in myeloid leukemia. Blood 2001;97:2784-90
   PubMed Web of Science ®Google Scholar
• Petit I, Szyper-Kravitz M, Nagler A, et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 2002;3:687-94
   PubMed Web of Science ®Google Scholar
• Aabideen K, Anoop P, Ethell ME, Potter MN. The feasibility of plerixafor as a second-line stem cell mobilizing agent in children. J Pediatr Hematol Oncol 2011;33:65-7
   PubMed Web of Science ®Google Scholar
• Uy GL, Rettig MP, Motabi IH, et al. A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood 2012;119:3917-24
   PubMed Web of Science ®Google Scholar
• Sison EA, Rau RE, McIntyre E, et al. MLL-rearranged acute lymphoblastic leukaemia stem cell interactions with bone marrow stroma promote survival and therapeutic resistance that can be overcome with CXCR4 antagonism. Br J Haematol 2013;160:785-97
   Google Scholar
• Ehlers S, Herbst C, Zimmermann M, et al. Granulocyte colony-stimulating factor (G-CSF) treatment of childhood acute myeloid leukemias that overexpress the differentiation-defective G-CSF receptor isoform IV is associated with a higher incidence of relapse. J Clin Oncol 2010;28:2591-7
   PubMed Web of Science ®Google Scholar
• Leget GA, Czuczman MS. Use of rituximab, the new FDA-approved antibody. Curr Opin Oncol 1998;10:548-51
   PubMedGoogle Scholar
• Thomas DA, O’Brien S, Faderl S, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol 2010;28:3880-9
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Thomas D, Wayne AS, O’Brien S. Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia. J Clin Oncol 2012;30:3876-83
   PubMed Web of Science ®Google Scholar
• Hoelzer D, Gokbuget N. Chemoimmunotherapy in acute lymphoblastic leukemia. Blood Rev 2012;26:25-32
   PubMed Web of Science ®Google Scholar
• Dworzak MN, Schumich A, Printz D, et al. CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy. Blood 2008;112:3982-8
   PubMed Web of Science ®Google Scholar
• Jandula BM, Nomdedeu J, Marin P, Vivancos P. Rituximab can be useful as treatment for minimal residual disease in bcr-abl-positive acute lymphoblastic leukemia. Bone Marrow Transplant 2001;27:225-7
   PubMed Web of Science ®Google Scholar
• Meinhardt A, Burkhardt B, Zimmermann M, et al. Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin’s lymphoma and Burkitt leukemia. J Clin Oncol 2010;28:3115-21
   PubMed Web of Science ®Google Scholar
• Goldman S, Smith L, Galardy P, et al. Rituximab with chemotherapy in children and adolescents with central nervous system and/or marrow-positive Burkitt lymphoma/leukaemia: a Children’s Oncology Group report. Br J Haematol 2014;167:394-401
   PubMed Web of Science ®Google Scholar
• Griffin TC, Weitzman S, Weinstein H, et al. A study of rituximab and ifosphamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Pediatr Blood Cancer 2009;52:177-81
   PubMed Web of Science ®Google Scholar
• Freeman SD, Kelm S, Barber EK, Crocker PR. Characterization of CD33 as a new member of the sialoadhesin family of cellular interaction molecules. Blood 1995;85:2005-12
   PubMed Web of Science ®Google Scholar
• Zein N, Sinha AM, McGahren WJ, Ellestad GA. Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science 1988;240:1198-201
   PubMed Web of Science ®Google Scholar
• Arceci RJ, Sande J, Lange B, et al. Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia. Blood 2005;106:1183-8
   PubMed Web of Science ®Google Scholar
• Zwaan CM, Reinhardt D, Corbacioglu S, et al. Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis. Blood 2003;101:3868-71
   PubMed Web of Science ®Google Scholar
• Brethon B, Auvrignon A, Galambrun C, et al. Efficacy and tolerability of gemtuzumab ozogamicin (anti-CD33 monoclonal antibody, CMA-676, Mylotarg) in children with relapsed/refractory myeloid leukemia. BMC Cancer 2006;6:172-9
   PubMed Web of Science ®Google Scholar
• Cooper TM, Franklin J, Gerling RB, et al. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children’s Oncology Group. Cancer 2012;118:761-9
   PubMed Web of Science ®Google Scholar
• Satwani P, Bhatia M, Garvin JHJr, et al. A phase I study of gemtuzumab ozogamicin (GO) in combination with busulfan and cyclophosphamide (Bu/Cy) and allogeneic stem cell transplantation in children with poor-risk CD33+ AML: a new targeted immunochemotherapy myeloablative conditioning (MAC) regimen. Biol Blood Marrow Transplant 2011;18:324-9
   Google Scholar
• Aplenc R, Alonzo TA, Gerbing RB, et al. Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children’s Oncology Group. J Clin Oncol 2008;26:2390-5
   PubMed Web of Science ®Google Scholar
• Franklin J, Alonzo TA, Hurwitz CA, et al. COG AAML03P1: efficacy and safety in a pilot study of intensive chemotherapy including gemtuzumab in children newly diagnosed with acute myeloid leukemia (AML). Blood 2008;112:136a; abstract
   Google Scholar
• Linenberger ML, Hong T, Flowers D, et al. Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood 2001;98:988-94
   PubMed Web of Science ®Google Scholar
• Roman E, Cooney E, Harrison L, et al. Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia. Clin Cancer Res 2005;11:S7164-70
   PubMed Web of Science ®Google Scholar
• Hauswirth AW, Florian S, Printz D, et al. Expression of the target receptor CD33 in CD34+/CD38−/CD123+ AML stem cells. Eur J Clin Invest 2007;37:73-82
   PubMed Web of Science ®Google Scholar
• Florian S, Sonneck K, Hauswirth AW, et al. Detection of molecular targets on the surface of CD34+/CD38− stem cells in various myeloid malignancies. Leuk Lymphoma 2006;47:207-22
   PubMed Web of Science ®Google Scholar
• Hasle H, Abrahamsson J, Forestier E, et al. Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML. 2004;Blood 2012;120:978-84
   Google Scholar
• Gamis A, Alonzo TA, Meshinchi S, et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531. J Clin Oncol 2014;32:3021-32
   PubMed Web of Science ®Google Scholar
• Rubnitz JE, Inaba H, Dahl G, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol 2010;11:543-52
   PubMed Web of Science ®Google Scholar
• Burnett AK, Russell NH, Hills RK, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol 2012;30:3940-31
   Google Scholar
• Castaigne S, Pautas C, Terre C, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 2012;379:1508-16
   PubMed Web of Science ®Google Scholar
• Estey EH, Giles FJ, Beran M, et al. Experience with gemtuzumab ozogamicin (“mylotarg”) and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood 2002;99:4222-4
   PubMed Web of Science ®Google Scholar
• Lo-Coco F, Cimino G, Breccia M, et al. Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood 2004;104:1995-9
   PubMed Web of Science ®Google Scholar
• Burnett AK, Hills RK, Milligan D, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML 15 trial. J Clin Oncol 2011;29:369-77
   PubMed Web of Science ®Google Scholar
• Kung Sutherland MS, Walter RB, Jeffrey SC, et al. SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrobenzodiazepine dimer is active in models of drug-resistant AML. Blood 2013;122:1455-63
   PubMed Web of Science ®Google Scholar
• Cesano A, Gayko U. CD22 as a target of passive immunotherapy. Semin Oncol 2003;30:253-7
   PubMed Web of Science ®Google Scholar
• Leung SO, Goldenberg DM, Dion AS, et al. Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2. Mol Immunol 1995;32:1413-27
   PubMed Web of Science ®Google Scholar
• Raetz EA, Cairo MS, Borowitz MJ, et al. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children’s Oncology Group Pilot Study. J Clin Oncol 2008;26:3756-62
   PubMed Web of Science ®Google Scholar
• Raetz EA, Cairo MS, Borawitz MJ, et al. Reinduction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL) in children, adolescents and young adults: results from Children’s Oncology Group (COG) study ADVL04P2. Blood 2011;118(suppl 1):573; abstract
   Google Scholar
• Morschhauser F, Kraeber-Bodere F, Wegener WA, et al. High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin’s lymphoma. J Clin Oncol 2010;28:3709-16
   PubMed Web of Science ®Google Scholar
• Chevallier P, Bodet-Milin C, Robillard N, et al. BCR-ABL1 molecular remission after 90Y-epratuzumab tetraxetan radioimmunotherapy in CD22+ Ph+ B-ALL: proof of principle. Eur J Haematol 2013;91:552-6
   PubMed Web of Science ®Google Scholar
• Thorson JS, Sievers EL, Ahlert J, et al. Understanding and exploiting nature’s chemical arsenal: the past, present and future of calicheamicin research. Curr Pharm Des 2000;6:1841-79
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Thomas D, Jorgensen J, et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory or relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol 2012;13:403-11
   PubMed Web of Science ®Google Scholar
• Fitzgerald DJ, Wayne AS, Kreitman RJ, Pastan I. Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates. Cancer Res 2011;71:6300-9
   PubMed Web of Science ®Google Scholar
• Wayne AS, Kreitman RJ, Findley HW, et al. Anti-CD22 immunotoxin RFB4 (dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. Clin Cancer Res 2010;16:1894-903
   PubMed Web of Science ®Google Scholar
• Mussai F, Campana D, Bhojwani D, et al. Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia. Br J Haematol 2010;150:352-8
   PubMed Web of Science ®Google Scholar
• Wayne AS, Bhojwani D, Silverman LB, et al. A novel anti-CD22 immunotoxin, moxetumomab pasudotox: phase I study in pediatric acute lymphoblastic leukemia (ALL). Blood 2011;118:248; abstract
   Web of Science ®Google Scholar
• Barta SK, Zou Y, Schindler J, et al. Synergy of sequential administration of a deglycosylated ricin A chain-containing combined anti-CD19 and anti-CD22 immunotoxin (Combotox) and cytarabine in a murine model of advanced acute lymphoblastic leukemia. Leuk Lymphoma 2012;53:1999-2003
   PubMed Web of Science ®Google Scholar
• Herrera L, Bostrom B, Gore L, et al. A phase 1 study of Combotox in pediatric patients with refractory B-lineage acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2009;31:936-41
   PubMed Web of Science ®Google Scholar
• Li D, Poon KA, Yu SF, et al. DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma. Mol Cancer Ther 2013;12:1255-65
   PubMed Web of Science ®Google Scholar
• Anderson KC, Bates MP, Slaughenhoupt BL, et al. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 1984;63:1424-33
   PubMed Web of Science ®Google Scholar
• Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008;321:974-7
   PubMed Web of Science ®Google Scholar
• Hoffman LM, Gore L. Blinatumomab, a bi-specific anti-CD19/CD3 BiTE® antibody for the treatment of acute lymphoblastic leukemia: perspectives and current pediatric applications. Front Oncol 2014;4:63
   PubMedGoogle Scholar
• Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res 2009;69:4941-4
   PubMed Web of Science ®Google Scholar
• Gore L, Zugmaier G, Handgretinger R, et al. Cytological and molecular remissions with blinatumomab treatment in second or later bone marrow relapse in pediatric acute lymphoblastic leukemia (ALL). J Clin Oncol 2013;31(Suppl15):10007; abstract
   Google Scholar
• Zugmaier G, Handgretinger R, Locatelli F, et al. A phase 1/2 study of blinatumomab in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Blood 2013;122:70; abstract
   Web of Science ®Google Scholar
• Topp MS, Kufer P, Gökbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011;29:2493-8
   PubMed Web of Science ®Google Scholar
• Topp MS, Goekbuget N, Zugmaier G, et al. Anti-CD19 BiTE blinatumomab induces high complete remission rate and prolongs overall survival in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL): an MRC UKALL12/ECOG 2993 study. Blood 2012;120(Suppl1):670; abstract
   Google Scholar
• Teachey DT, Rheingold SR, Maude SL, et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 2013;121:5154-7
   PubMed Web of Science ®Google Scholar
• Klinger M, Brandl C, Zugmaier G, et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T-cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood 2012;119:6226-33
   PubMed Web of Science ®Google Scholar
• Schlegel P, Lang P, Zugmaier G, et al. Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab. Haematologica 2014. [Epub ahead of print]
   Google Scholar
• Handgretinger R, Zugmaier G, Henze G, et al. Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia. Leukemia 2011;25:181-4
   PubMed Web of Science ®Google Scholar
• Topp M, Goekbuget N, Zugmaier G, et al. Clinical activity of anti-CD19 BiTE® blinatumomab in patients with relapse/refractory B-precursor acute lymphoblastic leukemia: Interim results of a phase 2 study. Haematologica 2011; abstract # 844
   Google Scholar
• Blanc V, Bousseau A, Caron A, et al. SAR3419 : an anti-CD19-maytansinoid immunoconjugate for the treatment of B-cell malignancies. Clin Cancer Res 2011;17:6448-58
   PubMed Web of Science ®Google Scholar
• Carol H, Szymanska B, Evans K, et al. The anti-CD19 antibody-drug conugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia. Clin Cancer Res 2013;19:1795-805
   PubMed Web of Science ®Google Scholar
• Fathi AT, Shah BD, De Angelo DJ, et al. A first-in-human phase 1 study of the antibody-drug conjugate SGN-CD19A in relapsed or refractory B-lineage acute leukemia and highly aggressive lymphoma. Blood 2013;122:1437; abstract
   PubMed Web of Science ®Google Scholar
• Park JH, Sauter C, Brentjens R. Cellular therapies in acute lymphoblastic leukemia. Hematol Oncol Clin North Am 2011;25:1281-301
   Google Scholar
• Brentjens RJ, Santos E, Nikhamin Y, et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res 2007;13:5426-35
   PubMed Web of Science ®Google Scholar
• Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013;368:1509-18
   PubMed Web of Science ®Google Scholar
• Leen AM, Myers GD, Sili U, et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 2006;12:1160-6
   PubMed Web of Science ®Google Scholar
• Marin V, Kakuda H, Dander E, et al. Enhancement of the anti-leukemic activity of cytokine induced killer cells with an anti-CD19 chimeric receptor delivering a 4-IBB-zeta activating signal. Exp Hematol 2007;35:1388-97
   PubMed Web of Science ®Google Scholar
• Tibes R, Keating MJ, Ferrajoli A, et al. Activity of alemtuzumab in patients with CD52-positive acute leukemia. Cancer 2006;106:2645-51
   PubMed Web of Science ®Google Scholar
• Angiolillo AL, Yu AL, Reaman G, et al. A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children’s Oncology Group report. Pediatr Blood Cancer 2009;53:978-83
   PubMed Web of Science ®Google Scholar
• Stock W, Sanford B, Lozanski G, et al. Alemtuzumab can be incorporated into front-line therapy of adult acute lymphoblastic leukemia (ALL): final phase I results of a Cancer and Leukemia Group B Study (CALGB 10102). Blood 2009;114; abstract # 838
   Google Scholar
• Laurenti L, Piccioni P, Cattani P, et al. Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia : incidence and treatment with oral ganciclovir. Haematologica 2004;89:1248-52
   PubMed Web of Science ®Google Scholar
• Moreno L, Pearson AD. How can attrition rates be reduced in cancer drug discovery? Expert Opin Drug Discov 2013;8:363-8
   PubMed Web of Science ®Google Scholar
• Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT01460160
   Google Scholar
• A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib. Available from: https://clinicaltrials.gov/ct2/show/NCT00777036
   Google Scholar
• A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL). Available from: https://clinicaltrials.gov/ct2/show/NCT01077544
   Google Scholar
• A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT01411267
   Google Scholar
• Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT01371981
   Google Scholar
• Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies. Available from: https://clinicaltrials.gov/ct2/show/NCT00908167
   Google Scholar
• Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT00557193
   Google Scholar
• A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT00866281
   Google Scholar
• Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT01371981
   Google Scholar
• Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL). Available from: https://clinicaltrials.gov/ct2/show/NCT01312818
   Google Scholar
• Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT00873093
   Google Scholar
• MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT01231919
   Google Scholar
• INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease. Available from: https://clinicaltrials.gov/ct2/show/NCT01164163
   Google Scholar
• Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT01154816
   Google Scholar
• AT9283 in Treating Young Patients With Relapsed or Refractory Acute Leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT01431664
   Google Scholar
• Trial of Sirolimus and Methotrexate in Relapsed/Refractory Lymphoblastic Leukemia and Lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT01162551
   Google Scholar
• Sirolimus in Treating Young Patients With Relapsed or Refractory Acute Leukemia or Non-Hodgkin’s Lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT00068302
   Google Scholar
• A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT01614197
   Google Scholar
• Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT01403415
   Google Scholar
• Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL (CRAD001NUS175T). Available from: https://clinicaltrials.gov/ct2/show/NCT01523977
   Google Scholar
• Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT00933985
   Google Scholar
• Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects. Available from: https://clinicaltrials.gov/ct2/show/NCT01177540
   Google Scholar
• A Phase II Study of 5-Azacitidine and Sargramostim as Maintenance Treatment After Definitive Therapy for Poor-risk AML or MDS. Available from: https://clinicaltrials.gov/ct2/show/NCT01700673
   Google Scholar
• Vorinostat in Children. Available from: https://clinicaltrials.gov/ct2/show/NCT01422499
   Google Scholar
• A Study Of Panobinostat In Children With Refractory Hematologic Malignancies. Available from: https://clinicaltrials.gov/ct2/show/NCT01321346
   Google Scholar
• AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT01798901
   Google Scholar
• A Phase I, Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015 in Haematological Malignancies. Available from: https://clinicaltrials.gov/ct2/show/NCT01713582
   Google Scholar
• POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients. Available from: https://clinicaltrials.gov/ct2/show/NCT01319864
   Google Scholar
• Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients. Available from: https://clinicaltrials.gov/ct2/show/NCT01516580
   Google Scholar
• Hyper CVAD Plus Ofatumumab in CD - 20 Positive Acute Lymphoblastic Leukemia (ALL). Available from: https://clinicaltrials.gov/ct2/show/NCT01363128
   Google Scholar
• Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL). Available from: https://clinicaltrials.gov/ct2/show/NCT00098839
   Google Scholar
• A Study Of Inotuzumab Ozogamicin Versus Investigator’s Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT01564784
   Google Scholar
• A Safety Study of SGN-CD33A in AML Patients. Available from: https://clinicaltrials.gov/ct2/show/NCT01902329
   Google Scholar
• Dose Escalation Safety and Pharmacokinetic Study of AVE9633 as Single Agent in Relapsed/Refractory CD33-Positive Acute Myeloid Leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT00543972
   Google Scholar
• SAR3419 in Acute Lymphoblastic Leukemia (MYRALL). Available from: https://clinicaltrials.gov/ct2/show/NCT01440179
   Google Scholar
• A Safety Study of SGN-CD19A for B-Cell Lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT01786135
   Google Scholar
• Ph 3 Trial of Blinatumomab vs Investigator’s Choice of Chemotherapy in Patients With Relapsed or Refractory ALL. Available from: https://clinicaltrials.gov/ct2/show/NCT02013167
   Google Scholar